

## Insights Into The Global Oligonucleotide Therapy Market 2022-2031 Forecast Period

The Business Research Company's Oligonucleotide Therapy Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, October 19, 2022 /EINPresswire.com/ --As per The Business Research Company's "Oligonucleotide Therapy Global Market Report 2022", the



oligonucleotide therapy market share is predicted to grow from \$0.98 billion in 2021 to \$1.10 billion in 2022 at a compound annual growth rate (CAGR) of 12.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple



Reports have been updated with the most recent Ukraine-Russia War impact on market growth for all 27+ industries. Reports also provide possible solutions and opportunities for surviving this crisis."

The Business Research Company countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The oligonucleotide therapy global market is expected to reach \$1.86 billion in 2026 at a CAGR of 14.0%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period.

Request A Sample Now To Gain A Better Understanding Of Oligonucleotide Therapy Market:

https://www.thebusinessresearchcompany.com/sample.as px?id=3398&type=smp

## Key Trends In The Oligonucleotide Therapy Market

The developers and providers of the oligonucleotide therapy global market are investing in oligonucleotide therapy market research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In August 2020, FDA granted accelerated approval to Viltepso (viltolarsen) injection, an antisense

oligonucleotide for the treatment of Duchenne muscular dystrophy (DMD), which is a genetic disorder, with reduced side effects.

Overview Of The Oligonucleotide Therapy Market

The oligonucleotide therapy market consists of sales of oligonucleotide therapy-related services by entities (organizations, sole traders, and partnerships) that manufacture oligonucleotide therapy products. Oligonucleotide therapy uses synthetic oligonucleotides, which can be artificially produced in labs, to inactivate disease-causing genes. Only goods and services traded between entities or sold to end consumers are included.

Learn More On The Global Oligonucleotide Therapy Market Report At: <a href="https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report">https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report</a>

Oligonucleotide Therapy Global Market Report 2022 from TBRC covers the following information:

Market Size Data

Forecast period: Historical and Future

By region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

By countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

**Market Segmentation** 

By Type: Antisense Oligonucleotide, Aptamer, Others

By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular

Diseases, Kidney Diseases, Others

By End User: Hospitals, Research Institutes.

By Geography: The global oligonucleotide therapy market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America holds the largest share in the market.

Major market players such as Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holdings ASA, Sarepta Therapeutics Inc., Jazz Pharmaceuticals and Bausch & Lomb.

Trends, Opportunities, Strategies And So Much More.

Oligonucleotide Therapy Global Market Report 2022 is one of The Business Research Company's comprehensive reports that provides an oligonucleotide therapy market forecast analyzes oligonucleotide therapy global market size, oligonucleotide therapy market growth drivers, oligonucleotide therapy market segments, oligonucleotide therapy global market major players, oligonucleotide therapy global market growth across geographies, and oligonucleotide therapy

global market competitors' revenues and market positioning. The oligonucleotide therapy global market report enables you to gain insights on opportunities and strategies, as well as identify countries and segments with the highest growth potential.

Not What You Were Looking For? Go Through Similar Reports By The Business Research Company:

Gene Editing Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Molecular Diagnostics Devices And Equipment Global Market Report 2022 <a href="https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-devices-and-equipment-global-market-report">https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-devices-and-equipment-global-market-report</a>

Nucleic Acid Based Gene Therapy Market 2022

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market

## About The Business Research Company?

The Business Research Company has published over 3000 industry reports, covering over 3000 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Get in touch with us -

The Business Research Company

Europe: +44 207 1930 708 Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

TBRC Blog: <a href="http://blog.tbrc.info/">http://blog.tbrc.info/</a>

LinkedIn: <a href="https://in.linkedin.com/company/the-business-research-company">https://in.linkedin.com/company/the-business-research-company</a>

Twitter: https://twitter.com/tbrc info

Facebook: <a href="https://www.facebook.com/TheBusinessResearchCompany">https://www.facebook.com/TheBusinessResearchCompany</a>
YouTube: <a href="https://www.youtube.com/channel/UC24">https://www.youtube.com/channel/UC24</a> fl0rV8cR5DxlCpgmyFQ

Global Market Model: <a href="https://www.thebusinessresearchcompany.com/global-market-model">https://www.thebusinessresearchcompany.com/global-market-model</a>

Healthcare Blog: <a href="https://healthcareresearchreports.com/">https://healthcareresearchreports.com/</a>

Oliver Guirdham The Business Research Company +44 20 7193 0708 email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/596703284

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 Newsmatics Inc. All Right Reserved.